Our Current Clinical Trials

We’re actively recruiting patients to participate in clinical trials to evaluate our therapeutic candidates. If you believe you or a loved one might be a good candidate for our trials, we encourage you to reach out directly via the link below.

Expanded Access Policy
Inbrx 101

INBRX-101

Our Recombinant Alpha-1 Anti- trypsin Fc-Fusion Protein (AAT-Fc)

INBRX-101 is a recombinant human AAT-Fc fusion protein therapeutic candidate currently being evaluated for the treatment of AATD. Early clinical data has demonstrated a promising pharmacokinetic profile that we believe supports a dosing schedule of every three weeks to achieve continuous normal AAT serum concentrations, a significant improvement from patients’ current regimen.

The Phase 1 dose-escalating trial for INBRX-101 is evaluating the effects of INBRX-101 on patients with Alpha-1 Antitrypsin Deficiency (AATD) who are either treatment naive or previously treated with plasma-derived therapeutics.

Learn more clinicaltrials.gov
Inbrx 109

INBRX-109

Our Tetravalent DR5 Agonist

INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.

The Phase 1 trial for INBRX-109 is currently enrolling combination treatment cohorts in pancreatic adenocarcinoma, malignant pleural mesothelioma, Ewing sarcoma, and colorectal cancer.

The Phase 2 trial for INBRX-109 is currently enrolling patients with unresectable or metastatic conventional chondrosarcoma.

Learn more Phase 1 Trial Phase 2 Trial
Inbrx 106

INBRX-106

Our Hexavalent OX40 Agonist

INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40, which is currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.

Parts 2 and 4, single agent dose expansion and dose expansion in combination with Keytruda, are currently enrolling in the following tumor types:

  • Solid Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Melanoma
  • Head and Neck Cancer
  • Gastric Cancer (GIST)
  • Renal Cell Carcinoma (RCC)
  • Urothelial Carcinoma
Learn more clinicaltrials.gov
Inbrx 105

INBRX-105

Our PD-L1 x 4-1BB Tetravalent Conditional Agonist

INBRX-105 is a tetravalent sdAb-based therapeutic candidate that’s currently being evaluated in patients with programmed death ligand 1 (PD-L1) expressing tumors, including those refractory to, or relapsed from, approved checkpoint inhibitor therapies. INBRX-105 is designed to agonize 4-1BB selectively in the presence of PD-L1.

The Phase 1 trial for INBRX-105 completed Part 1, single agent dose escalation, and is currently enrolling Parts 2 and 3, single agent dose expansion and dose escalation in combination with Keytruda, in the following tumor types:

  • Metastatic Solid Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Gastric Adenocarcinoma
  • Renal Cell Carcinoma (RCC)
  • Urothelial Carcinoma
  • Esophageal Adenocarcinoma
Learn more clinicaltrials.gov
Inbrx 121

INBRX-121

Our NKp46 Targeted Detuned IL-2